Pharmacokinetics of Immune Checkpoint Inhibitors Are Best Recapitulated in Human Immune System Mice (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0820; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Funding Other NIH Support Background Immune checkpoint inhibitors (ICIs) including anti-PD1 (Nivolumab) and CTLA-4 (Ipilimumab) treat a wide variety of cancers. The PBMC mice exhibited 227% increases in clearance compared to humanized mice and may not recapitulate human nivolumab PK. The humanized mouse model improves the translational application of ICI PK and associated toxicity outcomes compared to conventional preclinical mouse models."
Checkpoint inhibition • PK/PD data • Preclinical • Oncology • CTLA4
|
|
Yuxin Huang; Avisek Ghimire; Sarah C. Asby; Zander C. Kostka-Newman; John Rhey Mhar G. Garcia; Julie Lang; Lauren Aleksunes; Melanie S. Joy
|